Analysis of Membrane Type-1 Matrix Metalloproteinase (MT1-MMP, MMP14) in Eutopic and Ectopic Endometrium and in Serum and Endocervical Mucus of Endometriosis.
MT1-MMP
adenomyosis
endometriosis
endometrium
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
09 Oct 2023
09 Oct 2023
Historique:
received:
22
08
2023
revised:
26
09
2023
accepted:
04
10
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
Membrane type-matrix metalloproteinases (MT-MMPs) are a subgroup of the matrix metalloproteinases (MMPs) family and are key molecules in the degradation of the extracellular matrix. Membrane type-1 matrix metalloproteinase (MT1-MMP, MMP14) is often deregulated in different cancer tissues and body fluids of human cancer patients; however, MT1-MMP levels in endometriosis and adenomyosis patients are currently unknown. Tissue samples from patients with and without endometriosis or adenomyosis were analyzed with immunohistochemistry for the localization of MT1-MMP. Serum and endocervical mucus samples from patients with and without endometriosis or adenomyosis were investigated with MT1-MMP ELISAs. MT1-MMP was localized preferentially in the glands of eutopic and ectopic endometrium. MT1-MMP protein levels are significantly reduced in ovarian endometriosis (HSCORE = 31) versus eutopic endometrium (HSCORE = 91) and adenomyosis (HSCORE = 149), but significantly increased in adenomyosis (HSCORE = 149) compared to eutopic endometrium (HSCORE = 91). Similarly, analysis of the levels of MT1-MMP using enzyme-linked immune assays (ELISAs) demonstrated a significant increase in the concentrations of MT1-MMP in the serum of endometriosis patients (1.3 ± 0.8) versus controls (0.7 ± 0.2), but not in the endocervical mucus. Furthermore, MT1-MMP levels in the endocervical mucus of patients with endometriosis were notably reduced in patients using contraception (3.2 ± 0.4) versus those without contraception (3.8 ± 0.2). Taken together, our findings showed an opposite regulation of MT1-MMP in the tissue of ovarian endometriosis and adenomyosis compared to eutopic endometrium without endometriosis but increased serum levels in patients with endometriosis.
Sections du résumé
BACKGROUND
BACKGROUND
Membrane type-matrix metalloproteinases (MT-MMPs) are a subgroup of the matrix metalloproteinases (MMPs) family and are key molecules in the degradation of the extracellular matrix. Membrane type-1 matrix metalloproteinase (MT1-MMP, MMP14) is often deregulated in different cancer tissues and body fluids of human cancer patients; however, MT1-MMP levels in endometriosis and adenomyosis patients are currently unknown.
MATERIALS AND METHODS
METHODS
Tissue samples from patients with and without endometriosis or adenomyosis were analyzed with immunohistochemistry for the localization of MT1-MMP. Serum and endocervical mucus samples from patients with and without endometriosis or adenomyosis were investigated with MT1-MMP ELISAs.
RESULTS
RESULTS
MT1-MMP was localized preferentially in the glands of eutopic and ectopic endometrium. MT1-MMP protein levels are significantly reduced in ovarian endometriosis (HSCORE = 31) versus eutopic endometrium (HSCORE = 91) and adenomyosis (HSCORE = 149), but significantly increased in adenomyosis (HSCORE = 149) compared to eutopic endometrium (HSCORE = 91). Similarly, analysis of the levels of MT1-MMP using enzyme-linked immune assays (ELISAs) demonstrated a significant increase in the concentrations of MT1-MMP in the serum of endometriosis patients (1.3 ± 0.8) versus controls (0.7 ± 0.2), but not in the endocervical mucus. Furthermore, MT1-MMP levels in the endocervical mucus of patients with endometriosis were notably reduced in patients using contraception (3.2 ± 0.4) versus those without contraception (3.8 ± 0.2).
CONCLUSIONS
CONCLUSIONS
Taken together, our findings showed an opposite regulation of MT1-MMP in the tissue of ovarian endometriosis and adenomyosis compared to eutopic endometrium without endometriosis but increased serum levels in patients with endometriosis.
Identifiants
pubmed: 37893104
pii: biomedicines11102730
doi: 10.3390/biomedicines11102730
pmc: PMC10604514
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : German Academic Exchange Service
ID : 91560545 and 91731459
Références
Contraception. 2013 Feb;87(2):227-34
pubmed: 22995539
Lancet. 2004 Nov 13-19;364(9447):1789-99
pubmed: 15541453
Prog Mol Biol Transl Sci. 2017;147:1-73
pubmed: 28413025
Fertil Steril. 2018 Mar;109(3):380-388.e1
pubmed: 29566850
Semin Reprod Med. 2020 May;38(2-03):129-143
pubmed: 33032339
Am J Obstet Gynecol. 2001 Dec;185(6):1374-80
pubmed: 11744912
Fertil Steril. 2018 Mar;109(3):371-379
pubmed: 29566849
J Minim Invasive Gynecol. 2020 Feb;27(2):452-461
pubmed: 31816389
Hum Pathol. 2019 Jan;83:36-42
pubmed: 30120968
Obstet Gynecol Sci. 2017 Nov;60(6):579-586
pubmed: 29184867
Gynecol Obstet Invest. 1999;47 Suppl 1:3-9; discussion 9-10
pubmed: 10087422
Reprod Biol Endocrinol. 2010 Sep 24;8:113
pubmed: 20868473
Biology (Basel). 2022 Mar 26;11(4):
pubmed: 35453712
Mol Hum Reprod. 2006 Jan;12(1):11-8
pubmed: 16415334
Biomolecules. 2021 Nov 22;11(11):
pubmed: 34827737
Med Sci Monit. 2019 Oct 17;25:7770-7783
pubmed: 31619663
Diagnostics (Basel). 2022 Mar 22;12(4):
pubmed: 35453827
Reprod Sci. 2016 Oct;23(10):1371-80
pubmed: 27071964
Biochim Biophys Acta. 2012 Jan;1824(1):146-56
pubmed: 21982799
J Ovarian Res. 2021 Aug 3;14(1):101
pubmed: 34344453
Matrix Biol. 2015 May-Jul;44-46:207-23
pubmed: 25794647
Nat Rev Endocrinol. 2014 May;10(5):261-75
pubmed: 24366116
J Clin Med. 2020 Jun 18;9(6):
pubmed: 32570986
Virchows Arch. 2012 Nov;461(5):589-99
pubmed: 23011643
Int J Gynecol Pathol. 2009 Mar;28(2):148-56
pubmed: 19188819
J Turk Ger Gynecol Assoc. 2021 Jan 04;22(1):29-36
pubmed: 33389929
Medicine (Baltimore). 2021 Aug 13;100(32):e26545
pubmed: 34397871
Int J Mol Sci. 2020 Apr 18;21(8):
pubmed: 32325785
Gynecol Endocrinol. 2005 Aug;21(2):106-10
pubmed: 16109597
Folia Histochem Cytobiol. 2010 Jan 1;48(1):101-3
pubmed: 20529824
Thorac Cancer. 2020 Nov;11(11):3168-3174
pubmed: 32930509
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt A):1974-1988
pubmed: 28390905
Biol Reprod. 2000 Jan;62(1):85-94
pubmed: 10611071
PLoS One. 2018 Dec 7;13(12):e0208800
pubmed: 30532247
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4052-7
pubmed: 10737763
Fertil Steril. 2002 Oct;78(4):787-95
pubmed: 12372458
Reproduction. 2022 Oct 10;164(5):R101-R121
pubmed: 36099328
iScience. 2021 Mar 02;24(4):102258
pubmed: 33796844
Med Mol Morphol. 2005 Mar;38(1):43-6
pubmed: 16158179
Fertil Steril. 2012 Sep;98(3):511-9
pubmed: 22819144
Reprod Sci. 2015 Dec;22(12):1597-602
pubmed: 26138721
Eur J Obstet Gynecol Reprod Biol. 2003 Dec 10;111(2):197-203
pubmed: 14597251
Biomed Res Int. 2022 Jan 11;2022:7053521
pubmed: 35059465
N Engl J Med. 2009 Jan 15;360(3):268-79
pubmed: 19144942
Tumour Biol. 2014 Oct;35(10):9815-21
pubmed: 24986569
Biol Reprod. 2003 Sep;69(3):976-84
pubmed: 12773401
Dev Dyn. 2022 Feb;251(2):240-275
pubmed: 34241926
Arch Gynecol Obstet. 2020 Apr;301(4):1003-1011
pubmed: 32140805
EMBO J. 2015 Jul 14;34(14):1875-88
pubmed: 25991604
Cells. 2023 Aug 31;12(17):
pubmed: 37681919
Reprod Biomed Online. 2017 Nov;35(5):592-601
pubmed: 28693952
Gynecol Endocrinol. 2002 Oct;16(5):391-402
pubmed: 12587534
Expert Opin Ther Targets. 2022 Sep;26(9):761-765
pubmed: 36369916
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9120-5
pubmed: 8799164
Fertil Steril. 2011 Apr;95(5):1574-8
pubmed: 21315335